Light chain amyloidosis: Experience in a tertiary hospital: 2005-2013;Amiloidosis de cadenas ligeras: experiencia en un hospital terciario 2005-2013

Revista Clinica Espanola

Volumn 215, Issue 1, 2015, Pages 1-8

  Krsnik, I ^a   Cabero, M ^a   Morillo, D ^a   Segovia, J ^a   Garcia Pavia P ^a   Gomez Bueno M ^a   Salas, C ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Autologousprogenitortransplantation; Bortezomib; Free light chains; Heart transplantation; myloidosis; N terminalprohormone of brainnatriuretic peptide

Indexed keywords

ALKYLATING AGENT; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BORTEZOMIB;

ADULT; AMYLOIDOSIS; ARTICLE; ASTHENIA; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; DISEASE DURATION; DYSPNEA; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; EDEMA; FEMALE; HEART FAILURE; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HUMAN; LIGHT CHAIN; MALE; MIDDLE AGED; PLASMACYTOSIS; PNEUMONIA; TERTIARY CARE CENTER;

EID: 84920639910     PISSN: 00142565     EISSN: 15781860     Source Type: Journal    
DOI: 10.1016/j.rce.2014.08.013     Document Type: Article

References (23)

1. N. Leung, S.H. Nasr, and S. Sethi How I treat: Amyloidosis; the importante of accurate diagnosis and amyloid typing Blood 120 2012 3206 3213
2. J.D. Sipe, M.D. Benson, J.N. Buxbaum, S. Ikeda, G. Merlini, and M.J. Saraiva Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis Amyloid. 19 2012 167 170
3. a ed. 2008 International Agency for Research on Cancer Lyon 211
4. M. Gómez-Bueno, J. Segovia, P. García-Pavía, J.M. Barceló, I. Krsnik, and V. Sánchez-Turrión Amiloidosis cardiaca: la importancia del manejo multidisciplinario Rev Esp Cardiol 62 2009 698 702
5. M.E. Gatt, and G. Palladini Light chain amyloidosis 2012: A new era British J Haematol 160 2013 582 598
6. S.K. Kumar, A. Dispenzieri, M.Q. Lacy, S.R. Hayman, F.K. Buadi, and S.R. Zeldenrust Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis Am J Hematol 86 2011 251 255
7. G. Palladini, A. Dispenzieri, M.A. Gertz, S. Kumar, A. Wechalekar, and P.N. Hawkins New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: Impact on survival outcomes J Clin Oncol. 30 2012 4541 4549
8. S. Kumar, A. Dispenzieri, M.Q. Lacy, S.R. Hayman, F.K. Buadi, and C. Colby Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements J Clin Oncol 30 2012 989 995
9. E. Kastritis, A. Anagnostopoulos, M. Roussou, S. Toumanidis, C. Pamboukas, and M. Migkou Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone Haematologica 92 2007 1351 1358
10. G. Merlini, A.D. Wechalekar, and G. Palladini Systemic light chain amyloidosis: An update for treating physicians Blood 121 2013 5124 5130
11. P. García-Pavía, P. Avellana, B. Bornstein, D. Heine-Suñer, M. Cobo-Marcos, and M. Gómez-Bueno Abordaje familiar en la amiloidosis cardiaca hereditaria por transtiretina Rev Esp Cardiol 64 2011 523 526
12. M.M. Oken, R.H. Creech, D.C. Tormey, J. Horton, T.E. Davis, and E.T. McFadden Toxicity and reponse criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 5 1982 649 655
13. F.J. De Haro-del Moral, A. Sánchez-Lajusticia, M. Gómez-Bueno, P. García-Pavía, C. Salas-Antón, and J. Segovia-Cubero Role of cardiac scintigraphy with 99mTc-DPD in the differentiation of cardiac amyloidosis subtype Rev Esp Cardiol (Engl Ed.) 65 2012 440 446
14. R.L. Comenzo, D. Reece, G. Palladini, D. Seldin, V. Sanchorawala, and H. Landau Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis Leukemia 26 2012 2317 2325
15. A.D. Wechalekar, S.O. Schonland, E. Kastritis, J.D. Gillmore, M.A. Dimopoulos, and T. Lane A European collaborative study of treatment outcomes in 346 patients with cardiac stage iii AL amyloidosis Blood 121 2013 3420 3427
16. S. Dinner, W. Witteles, R. Witteles, A. Lam, S. Arai, and R. Lafayette The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis Br J Haematol. 161 2013 367 372
17. S.K. Kumar, S.R. Hayman, F.K. Buadi, V. Roy, M.Q. Lacy, and M.A. Gertz Lenalidomide, cyclophosphamide and dexamethasone (CRd) for light-chain amyloidosis: Long-term results from a phase 2 trial Blood 119 2012 4860 4867
18. T.V. Kourelis, M. Gertz, C. Zent, M. Lacy, R. Kyle, and P.S. Kapoor Systemic amiloidosis asssociated with chronic lymphocytic leukemia/small lymphocytic lymphoma Am J Hematol 88 2013 375 378
19. M.T. Cibeira, V. Sanchorawala, D.C. Seldin, K. Quillen, J.L. Berk, and L.M. Dember Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: Long-term results in a series of 421 patients Blood 118 2011 4346 4352
20. M.L. Sorror, S. Giralt, B.M. Sandmaier, M. De Lima, M. Shajahan, and D.G. Maloney Hematopoietic cell transplantation-specific comorbidity index as an outcome predictor for patients with acute myeloid leukaemia in first remission: Combined FHCRC and MDACC experiences Blood 110 2007 4606 4613
21. J.R. Mikhael, S.R. Schuster, V.H. Jimenez-Zepeda, N. Bello, J. Spong, and C.B. Reeder Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis Blood 119 2012 4391 4394
22. E. Roig, L. Almenar, F. González-Vilchez, G. Rábago, J. Delgado, and M. Gómez-Bueno Outcomes of heart transplantation for cardiac amyloidosis; subanalysis of the Spanish Registry for Heart Transplantation Am J Transplant 9 2009 1414 1419
23. P. García-Pavía, M.T. Tomé-Esteban, and C. Rapezzi Amyloidosis: Also a cardiac disease Rev Esp Cardiol 64 2011 797 808